589
Views
17
CrossRef citations to date
0
Altmetric
Review Article

Effects of immunomodulators on the response induced by vaccines against autoimmune diseases

ORCID Icon
Pages 393-402 | Received 02 Jul 2017, Accepted 26 Aug 2017, Published online: 14 Sep 2017

References

  • Atassi MZ, Casali P. Molecular mechanisms of autoimmunity. Autoimmunity. 2008;41:123–132.
  • Doyle HA, Yang M-L, Raycroft MT, et al. Autoantigens: novel forms and presentation to the immune system. Autoimmunity. 2014;47:220–233.
  • Lerner A, Jeremias P, Matthias T. The world incidence and prevalence of autoimmune diseases is increasing. Int J Celiac Dis. 2015;3:151–155.
  • Versini M, Jeandel PY, Bashi T, etet al. Unraveling the Hygiene Hypothesis of helminths and autoimmunity: origins, pathophysiology, and clinical applications. BMC Med. 2015;13:81.
  • Gause WC, Wynn TA, Allen JE. Th2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nat Rev Immunol. 2013;13:607–614.
  • Guimarães LE, Baker B, Perricone C, et al. Vaccines, adjuvants and autoimmunity. Pharmacol Res. 2015;100:190–209.
  • van der Laan JW, Gould S, Tanir JY. ILSI HESI Vaccines and Adjuvants Safety Project Committee. Safety of vaccine adjuvants: focus on autoimmunity. Vaccine. 2015;33:1507–1514.
  • Clark R, Kupper T. Old meets new: the interaction between innate and adaptive immunity. J Investig Dermatol. 2005;125:629–637.
  • Takeda K, Akira STLR. signaling pathways. Semin Immunol. 2004;16:3–9.
  • Bedoya SK, Lam B, Lau K, et al. Th17 cells in immunity and autoimmunity. Clin Dev Immunol. 2013;2013:986789.
  • Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev. 2014;13:668–677.
  • Jackson JA, Friberg IM, Little S, et al. Review series on helminths, immune modulation and the hygiene hypothesis: immunity against helminths and immunological phenomena in modern human populations: coevolutionary legacies?. Immunology. 2008;126:18–27.
  • Zaccone P, Cooke A. Vaccine against autoimmune disease: can helminths or their products provide a therapy? Curr Opin Immunol. 2013;25:418–423.
  • Araujo MI, Hoppe BS, Medeiros M, et al. Schistosoma mansoni infection modulates the immune response against allergic and auto-immune diseases. Mem Inst Oswaldo Cruz. 2004;99(Suppl I):27–32.
  • Conrad ML, Renz H, Blaser K. Immunological approaches for tolerance induction in allergy. Curr Topics Microbiol Immunol. 2011;352:1–26.
  • Baird FJ, Lopata AL. The dichotomy of pathogens and allergens in vaccination approaches. Front Microbiol. 2014;5:365.
  • Mannie MD, Curtis AD. Tolerogenic vaccines for multiple sclerosis. Hum Vaccin Immunother. 2013;9:1032–1038.
  • Hussaarts L, Yazdanbakhsh M, Guigas B. Priming dendritic cells for Th2 polarization: lessons learned from helminths and implications for metabolic disorders. Front Immunol. 2014;5:499.
  • Okano M, Satoskar AR, Nishizaki K, et al. Lacto-N-fucopentaose III found on Schistosoma mansoni egg antigens functions as adjuvant for proteins by inducing Th2-type response. J Immunol. 2001;167:442–450.
  • Kuijk LM, van Die I. Worms to the rescue: can worm glycans protect from autoimmune diseases? IUBMBLife. 2010;62:303–312.
  • Clark JF. The role of glycans in immune evasion: the human fetoembryonic defence system hypothesis revisited. Mol Hum Reprod. 2014;20:185–199.
  • Hewitson JP, Grainger JR, Maizels RM. Helminth immunoregulation: the role of parasite secreted proteins in modulating host immunity. Mol Biochem Parasitol. 2009;167:1–11.
  • Rasko DA, Wang G, Monteiro MA, et al. Synthesis of mono- and di-fucosylated type I Lewis blood group antigens by Helicobacter pylori. Eur J Biochem. 2000;267:6059–6066.
  • Lebwohl B, Blaser MJ, Ludvigsson JF, et al. Decreased risk of celiac disease in patients with Helicobacter pylori colonization. Am J Epidemiol. 2013;178:1721–1730.
  • Taghipour N, Aghadei HA, Haghighi A, et al. Potential treatment of inflammatory bowel disease: a review of helminths therapy. Gastroenterol Hepatol Bed Bench. 2014;7:9–16.
  • Helmby H. Human helminth therapy to treat inflammatory disorders: where do we stand?. BMC Immunol. 2015;37:208–214.
  • Marciani DJ. New Th2 adjuvants for preventive and active immunotherapy of neurodegenerative proteinopathies. Drug Discov Today. 2014;19:912–920.
  • Hirsch DL, Ponda P. Antigen-based immunotherapy for autoimmune disease: current status. Immunotargets Ther. 2014;4:1–11.
  • Ramshaw IA, Fordham SA, Bernard CCA, et al. DNA vaccines for the treatment of autoimmune diseases. Immunol Cell Biol. 1997;75:409–413.
  • Klinman DM, Conover J, Bloom ET, et al. Immunogenicity and efficacy of a DNA vaccine in aged mice. J Gerontol A Biol Sci Med Sci. 1998;53A:B281–B286.
  • Pawelec G, Lutsgarten J, Ruby C, et al. Impact of aging on cancer immunity and immunotherapy. Cancer Immunol Immunother. 2009;58:1907–1908.
  • Garren H, Ruiz PJ, Watkins TA, et al. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity. 2001;15:15–22.
  • Blanchfield JL, Mannie MD. A GMCSF-neuroantigen fusion protein is a potent tolerogen in experimental autoimmune encephalomyelitis (EAE) that is associated with efficient targeting of neuroantigen to APC. J Leukoc Biol. 2010;83:509–521.
  • Mannie MD, Blanchfield JL, Islam SM, et al. Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis. Front Immunol. 2012;3:255.
  • Mannie MD, Abbott DJ, Blanchfield JL. Experimental autoimmune encephalomyelitis in Lewis rats: IFN-β acts as a tolerogenic adjuvant for induction of neuroantigen-dependent tolerance. J Immunol. 2009;182:5331–5341.
  • Van Monfort T, Melchers M, Isik G, et al. A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T-cell responses. J Biol Chem. 2011;286:22250–22261.
  • Islam SM, Curtis IIAD, Taslim N, et al. GM-CSF-neuroantigen fusion protein reverse experimental autoimmune encephalomyelitis and mediate tolerogenic activity in adjuvant-primed environments: association with inflammation dependent, inhibitory antigen presentation. J Immunol. 2014;193:2317–2329.
  • Marciani DJ. Alzheimer's disease vaccine development: A new strategy focusing on immune modulation. J Neuroimmunol. 2015;287:54–63.
  • Anderson RP, Jabri B. Vaccine against autoimmune disease: antigen specific immunotherapy. Curr Opin Immunol. 2013;25:410–417.
  • Sayegh MH, Akalin E, Hancock WW, et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med. 1995;181:1869–1874.
  • Esensten JH, Helou YA, Chopra G, et al. CD28 costimulation: from mechanism to therapy. Immunity. 2016;44:973–988.
  • Luo X, Miller SD, Shea LD. Immune tolerance for autoimmune disease and cell transplantation. Annu Rev Biomed Eng. 2016;18:181–205.
  • He S-X, Gershwin ME, Ansari AA. Checkpoint-based immunotherapy for autoimmune diseases: opportunities and challenges. J Autoimmun. 2017;79:1–3.
  • Faria AMC, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol. 2006;13:143–157.
  • Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009;9:287–293.
  • Spreafico R, Ricciardi-Castagnoli P, Mortellaro A. The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants. Eur J Immunol. 2010;40:638–653.
  • Seubert A, Calabro S, Santini L, et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci USA. 2011;108:11169–11174.
  • Weng NP, Akbar AN, Goronzy J. CD28¯ T-cells: their role in the age-associated decline of immune function. Trends Immunol. 2009;30:306–312.
  • Schultze V, D’Agosto V, Wack A, et al. Safety of MF59 adjuvant. Vaccine. 2008;26:3209–3222.
  • O’Hagan DT, Ott GS, De Gregorio E, et al. The mechanism of action of MF59: an innately attractive adjuvant formulation. Vaccine. 2012;30:4341–4348.
  • Calabro S, Tritto E, Pezzotti A, et al. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine. 2013;31:3363–3369.
  • Maggio ET. Polysorbates, peroxides, protein aggregation, and immunogenicity – a growing concern. J Excipients and Food Chem. 2012;3:45–53.
  • Rhodes J, Chen H, Hall SR, et al. Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugs. Nature. 1995;377:71–75.
  • Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today. 2003;8:934–945.
  • Mahurkar S, Suppiah V, O’Doherty C. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. Autoimmun Rev. 2014;13:178–186.
  • Duda PW, Schmied MC, Cook SL, et al. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Investig. 2000;105:967–976.
  • Conner J. Glatiramer acetate and therapeutic peptide vaccines for multiple sclerosis. J Autoimmun Cell Res. 2014;1:3.
  • Zheng B, Switzer K, Marinova E, et al. Exacerbation of autoimmune arthritis by copolymer-I through promoting type 1 immune response and autoantibody production. Autoimmunity. 2008;41:363–371.
  • Koronyo Y, Salumbides BC, Sheyn J, et al. Therapeutic effects of glatiramer acetate and grafted CD115+ monocytes in a mouse model of Alzheimer’s disease. Brain. 2015;138:2399–2422.
  • Marciani DJ. A retrospective analysis of the Alzheimer’s disease vaccine progress: the critical need for new development strategies. J Neurochem. 2016;137:687–700.
  • Garcia-Vallejo JJ, van Kooyk Y. DC-SIGN: The strange case of Dr. Jekyll and Mr. Hyde. Immunity. 2015;42:983–985.
  • Shade K-TC, Anthony RM. Antibody glycosylation and inflammation. Antibodies. 2013;2:392–414.
  • Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann N Y Acad Sci. 2012;1253:170–180.
  • Sloan-Lancaster J, Evavold BD, Allen PM. Th2 cell clonal anergy as a consequence of partial activation. J Exp Med. 1994;180:1195–1205.
  • Licastro F, Candore G, Lio D, et al. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing. 2005;2:8.
  • Van Kooyk Y, Geijtenbeek TBH. DC-SIGN: escape mechanism for pathogens. Nat Rev Immunol. 2003;3:697–709.
  • Thomas PG, Carter MR, Atochina O, et al. Maturation of dendritic cell 2 phenotype by a helminth glycan uses a toll-like receptor 4-dependent mechanism. J Immunol. 2003;171:5837–5841.
  • Gringhuis SI, Kaptein TM, Wevers BA, et al. Fucose-specific DC-SIGN signaling directs T helper cell tytpe-2 responses via IKKε- and CYLD-dependent Bcl3 activation. Nat Commun. 2014;5:3898.
  • Kensil CR, Soltysik S, Patel U, et al. Structure/function relationship in adjuvants from Quillaja saponaria Molina. In: Brown F, Chanock RM, Ginsberg HS, Lerner RA, editors. Vaccines 92. New York: Cold Spring Harbor Lab Press; 1992; p. 35–40.
  • Tso C-L, Zisman A, Pantuck A, et al. Cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-stimulating factor. Cancer Res. 2001;61:7925–7933.
  • Wang Y, Da’Dara AA, Thomas PG, et al. Dendritic cells activated by an anti-inflammatory agent induce CD4+ T helper type 2 responses without impairing CD8+ memory and effector cytotoxic T-lymphocyte responses. Immunology. 2010;129:406–417.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.